Articles by Disease (Basal Ganglia Diseases)

Consequences of Elevated Homocysteine During Embryonic Development and Possible Modes of Action

Journal: Current Pharmaceutical Design
Volume: 10
Page: 2719-2732
Author(s): P. R. Brauer and B. J. Tierney

Metal and Inflammatory Targets for Alzheimers Disease

Journal: Current Drug Targets
Volume: 5
Page: 535-551
Author(s): Jack T. Rogers and Debomoy K. Lahiri

Pharmacological Neuroprotection in Stroke: Rationale, State-of-the-art and Future Directions

Journal: Current Neuropharmacology
Volume: 2
Page: 265-276
Author(s): Francesco Orzi, Giuliano Sette, Ping Zhou and Costantino Iadecola

Neuroprotective Strategies for Parkinsons Disease

Journal: Current Neuropharmacology
Volume: 2
Page: 309-322
Author(s): Ippolita Cantuti-Castelvetri and David G. Standaert

Possible Neuroprotective Strategies for Huntingtons Disease

Journal: Current Neuropharmacology
Volume: 2
Page: 331-342
Author(s): James G. Greene

Bivalent Ligands for G Protein-Coupled Receptors

Journal: Current Pharmaceutical Design
Volume: 10
Page: 2015-2020
Author(s): William S. Messer and Jr.

The Use of Antiparkinsonian Agents in the Management of Drug-Induced Extrapyramidal Symptoms

Journal: Current Pharmaceutical Design
Volume: 10
Page: 2239-2248
Author(s): K. Burgyone, K. Aduri, J. Ananth and S. Parameswaran

Neuroprotection by the α2-Adrenoceptor Agonist, Dexmedetomidine, in Experimental Stroke Models

Journal: Vascular Disease Prevention (Discontinued)
Volume: 1
Page: 117-122
Author(s): Kirsi Puurunen, Jukka Jolkkonen and Juhani Sivenius

Proteomic Approaches Contributing to the Understanding of Neurodegenerative Diseases: Focus on Alzheimers Disease

Journal: Current Proteomics
Volume: 1
Page: 221-229
Author(s): Ephrem Engidawork and Gert Lubec

G Protein-Coupled Receptors and their Signaling Pathways: Classical Therapeutical Targets Susceptible to Novel Therapeutic Concepts

Journal: Current Pharmaceutical Design
Volume: 10
Page: 1937-1958
Author(s): Claus Liebmann